The IMF Symposium Is My Appetizer to ASH

Michael Tuohy |

The rain has cleared and on Friday, our day started with the IMF Satellite Symposium. This is like an appetizer to ASH and gives a glimpse into what we’ll be updated on in the next days. This program is moderated by Dr. Brian G.M. Durie, who takes us through various case studies. All attendees are then given the opportunity to vote on how they would treat. We are then presented with one of the multiple myeloma expert panelists who discusses available clinical data that could guide the treatment choice for the case. I enjoy the audience input by voting before and after the data to see if decisions were changed.

Faculty Presenters:

  • Brian G.M. Durie, MD (Program Director)
  • Shaji Kumar, MD, Mayo Clinic, Rochester, MN
  • Philippe Moreau, MD, University Hospital Hotel-Dieu, Nantes, France
  • Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN
  • Jesus F. San-Miguel, MD, PhD, Universidad de Navarra, Pamplona, Spain

Case discussions:

  • Case Discussion 1: Risk Stratification of Plasma Cell Disorders
  • Case Discussion 2: Are we ready for personalized therapy in Newly Diagnosed MM?
  • Case Discussion 3: Considering the Recent Data on Transplantation, Consolidation, and Maintenance After Induction Therapy
  • Case Discussion 4: Advances in the Optimal Choice of Therapeutic Strategies for Patients With Relapsed/Refractory Disease

Interesting to me: Many novel therapies over the years have been approved in the US, which provides us greater access and treatment options outside of clinical trials. In Europe, the gold standard upfront therapy continues to include autologous stem cell transplant (ASCT). A big question from members of our Connecticut support group members, is whether to transplant upfront, at 1st remission, or save for later? This year, at ASH, the European standard remains to transplant upfront (for standard-risk myeloma.) Dr. Rajkumar stated at Friday’s IMF Symposium that while he still agrees in the benefit of transplant up front, that considering quality of life, and if a patient has an active life style, or work schedule, to harvest the stem cells early and consider the ASCT at first relapse but not to wait longer than that.

Robin and I went to see Jeff Lynne’s Electric Light Orchestra concert this summer at Madison Square Garden. Here’s a song by Electric Light Orchestra “shedding light and blue skies” on ASH:

Comments are closed.